Entity
  • OMass Therapeutics

    Created in 2016
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    592 6,485
  • Activities

  • Technologies

  • Entity types

  • Location

    Chancellor Court, John Smith Dr, Oxford Business Park, Oxford OX4 2GX, UK

    Oxford

    United Kingdom

  • Employees

    Scale: 11-50

    Estimated: 82

  • Engaged corporates

    14
    3 6
  • Added in Motherbase

    1 year, 9 months ago
Description
  • Value proposition

    OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors, addressing severe unmet medical needs. OMass is backed by Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures and British Patient Capital.

Corporate interactions BETA
Corporate TypeTweets Articles
Johnson & Johnson
Johnson & Johnson
Pharmaceutical, Hospitals and Health Care
Johnson & Johnson
Pharmaceutical, Hospitals and Health Care
Other

7 Sep 2020


Bayer
Bayer
Pharmaceutical, Chemistry, Chemical Manufacturing
Bayer
Pharmaceutical, Chemistry, Chemical Manufacturing
Other

2 Aug 2019


 EU Green Capital
EU Green Capital
European Union, Environmental Services
EU Green Capital
European Union, Environmental Services
Other

8 May 2019


Sanofi
Sanofi
Pharmaceutical, Pharmaceutical Manufacturing
Sanofi
Pharmaceutical, Pharmaceutical Manufacturing
Other

20 Sep 2024


Similar entities
Loading...
Loading...
Social network dynamics